The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
Open accessAbstract
Aims/hypothesis Obesity and insulin resistance are associated with low-grade chronic inflammation. Glucagon-like peptide-1 (GLP-1) is known to reduce insulin resistance. We investigated whether GLP-1 has anti-inflammatory effects on adipose tissue, including adipocytes and adipose tissue macrophages (ATM).Methods We administered a recombinant adenovirus (rAd) producing GLP-1 (rAd-GLP-1) to an ob/ob mouse model of diabetes. We examined insulin sensitivity, body fat mass, the infiltration of ATM and metabolic profiles. We analysed the mRNA expression of inflammatory cytokines, lipogenic genes, and M1 and M2 macrophage-specific genes in adipose tissue by real-time quantitative PCR. We also examined the activation of nuclear factor κB (NF-κB), extracellular signal-regulated kinase 1/2 and Jun N-terminal kinase (JNK) in vivo and in vitro.Results Fat mass, adipocyte size and mRNA expression of lipogenic genes were significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Macrophage populations (F4/80(+) and F4/80(+)CD11b(+)CD11c(+) cells), as well as the expression and production of IL-6, TNF-α and monocyte chemoattractant protein-1, were significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Expression of M1-specific mRNAs was significantly reduced, but that of M2-specific mRNAs was unchanged in rAd-GLP-1-treated ob/ob mice. NF-κB and JNK activation was significantly reduced in adipose tissue of rAd-GLP-1-treated ob/ob mice. Lipopolysaccharide-induced inflammation was reduced by the GLP-1 receptor agonist, exendin-4, in 3T3-L1 adipocytes and ATM.Conclusions/interpretation We suggest that GLP-1 reduces macrophage infiltration and directly inhibits inflammatory pathways in adipocytes and ATM, possibly contributing to the improvement of insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the adipose tissue of GLP-1-treated ob/ob mice expressing recombinant adenovirus, for instance, GLP-1RA has been shown to decrease the production of TNF-α, IL-6, and IL-1β, all of which are significant mediators of inflammation.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“antiinflammatory benefits have been observed in various preclinical models, such as obesity, atherosclerosis, steatohepatitis, and nephritis, even in the absence of direct immune cell targeting (27–32).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was reported that GLP-1 shows anti-inflammatory effects on pancreatic islets and adipose tissue, contributing to lowering glucose levels in diabetes [18–20].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Administration of a recombinant adenovirus producing GLP-1 (4 × 109 PFU/mouse) to ob/ob mice reduced the macrophage population and production of TNF-α, MCP-1, and IL-6 in adipose tissue via inhibition of nuclear factor-kappa B (NF-κB) activation and phosphorylation of ERK1/2 and c-Jun N-terminal kinases [18].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 receptor agonists may potentially reduce inflammation and oxidative stress in adipose tissue by affecting the expression of cytokines, chemokines, and macrophage infiltration, with prolonged GLP-1 action potentially alleviating obesity-related adipose tissue inflammation while enhancing the expression of anti-inflammatory genes [17,18]”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [17]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Similar antiinflammatory effects of GLP-1 have been reported in human macrophage cell lines (66), and systemic effects of GLP-1 agonists on macrophage infiltration have been previously reported (67).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [67]
In the citing paper
“Treatment of Huh7 and HepG2 hepatoma cells with exenatide decreased intracellular lipid accumulation [181,182] by enhancing fatty acid oxidation and reducing lipogenesis [160,161,179,183].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [182]
In the citing paper
“Treatment with GLP-1 RAs is also able to reduce macrophage infiltration of adipose tissue and inhibit inflammatory pathways in adipocytes, concurring to ameliorate insulin sensitivity [138].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [138]
In the citing paper
“In fact, new research suggests that GLP-1 RAs may reduce the production of pro-inflammatory cytokines and immune cell infiltration to reduce inflammation in many tissues, including AT [73].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [73]
In the citing paper
“Furthermore, GLP-1 RAs prevent resident macrophages in AT from being activated by nuclear factor-kappa B (NF-κB) [73].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [73]
In the citing paper
“Studies have shown that GLP-1 and its analogs have anti-inflammatory properties.”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard, J., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., Vidal, H., Capeau, J., & Fève, B. (2006) · PubMed · Cited by 2,090
NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase
Nidai Ozes, O., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999) · Nature · doi:10.1038/43466 · Cited by 1,832
IKK-β links inflammation to obesity-induced insulin resistance
Arkan, M. C., Hevener, A. L., Greten, F. R., Maeda, S., Li, Z.-W., Long, J. M., Wynshaw-Boris, A., Poli, G., Olefsky, J., & Karin, M. (2005) · Nature Medicine · doi:10.1038/nm1185 · Cited by 1,773
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335c1 · Cited by 1,425
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 319
Gassen, N. V., Staels, W., Overmeire, E. V., Groef, S. D., Sojoodi, M., Heremans, Y., Leuckx, G., de Casteele, M. V., Ginderachter, J. A. V., Heimberg, H., et al. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0272 · Cited by 43
Elkhatib, M. A. W., Mroueh, A., Rafeh, R. W., Sleiman, F., Fouad, H. H., Saad, E. I., Fouda, M. A., Elgaddar, O., Issa, K., Eid, A. H., et al. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.009 · Cited by 41
Wu, D., Yan, Z.-B., Cheng, Y., Zhong, M., Liu, S.-Z., Zhang, G., & Hu, S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.015 · Cited by 40
Liu, H., Zheng, J., Zheng, T.-J., & Wang, P. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105801 · Cited by 40
Liraglutide pretreatment attenuates sepsis-induced acute lung injury
Baer, B., Putz, N. D., Riedmann, K. J., Gonski, S. K., Lin, J., Ware, L. B., Toki, S., Peebles, R. S., Cahill, K. N., & Bastarache, J. A. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00041.2023 · Cited by 43
Codium fragile Ameliorates High-Fat Diet-Induced Metabolism by Modulating the Gut Microbiota in Mice
Kim, J., Choi, J. H., Oh, T., Ahn, B.-J., & Unno, T. (2020) · Nutrients · doi:10.3390/nu12061848 · Cited by 41
Diz-Chaves, Y., Toba, L., Fandiño, J., González-Matías, L. C., García‐Segura, L. M., & Mallo, F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1370-7 · Cited by 39
Zhao, J., Zhao, Y., Hu, Y., & Peng, J. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00276-7 · Cited by 37
Zhu, R., & Chen, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095432 · Cited by 38
Adipose Tissue Insulin Resistance: A Key Driver of Metabolic Syndrome Pathogenesis
Rabiee, A., Hossain, M. A., & Poojari, A. (2025) · Biomedicines · doi:10.3390/biomedicines13102376 · Cited by 48
Liang, Y., Li, Z., Liang, S., Li, Y., Yang, L., Lu, M. S., Gu, H. F., & Xia, N. (2016) · Nutrition and Diabetes · doi:10.1038/nutd.2015.37 · Cited by 35
Li, Z., Zhu, Y., Li, C., Tang, Y., Jiang, Z., Yang, M., Ni, C., Li, D., Chen, L., & Niu, W. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0836-x · Cited by 35
Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors
Nakamura, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.840 · Cited by 35
Wu, H., Mao, X.-F., Fan, H. J., & Wang, Y. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.107102 · Cited by 34
Yu, Y., Cui, S., Zheng, T.-N., Ma, H., Xie, Z., Jiang, H., Li, Y., Zhu, K., Huang, C., Li, J. X., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0427-1 · Cited by 34
Rizzo, M., Nikolić, D., Banach, M., Giglio, R. V., Patti, A. M., Bartolo, V. D., Tamburello, A., Zabbara, A., Pecoraro, G., Montalto, G., et al. (2013) · Clinical Lipidology · doi:10.2217/clp.13.8 · Cited by 34
Guo, H., Li, H., Wang, B., Ding, W. Q., Ling, L., Yang, M., Gu, Y., & Niu, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000464118 · Cited by 32
Kim, J. B., Lee, G. Y., Maeng, H. J., Kim, H., Bae, J. H., Kim, K. M., & Lim, S. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.781 · Cited by 33
Piątkowska‐Chmiel, I., Gawrońska‐Grzywacz, M., Popiołek, Ł. P., Herbet, M., & Dudka, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-10187-y · Cited by 34
Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 35
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells
Choung, J.-S., Lee, Y.-S., & Jun, H.-S. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0078 · Cited by 31
Self-citationRenner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 30
Shah, F. A., Mahmud, H., Gallego‐Martin, T., Jurczak, M. J., O'Donnell, C. P., & McVerry, B. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00296 · Cited by 32
GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Chen, Y., Xu, Y.-N., Ye, C.-Y., Feng, W., Zhou, Q., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00836-9 · Cited by 32
Obesity, immunomodulation and chronic kidney disease
Börgeson, E., & Sharma, K. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.011 · Cited by 30
Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats
Tanaka, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2653 · Cited by 29
Zhang, X., Han, X.-W., Jiang, Y., Wang, Y., He, X.-L., Liu, D., Huang, J., Liu, H.-H., Ye, T., Li, S.-J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110747 · Cited by 29
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 31
Liraglutide reduces body weight by upregulation of adenylate cyclase 3
Li, Z., Liang, Y., Xia, N., Lai, Y., Pan, H., Zhou, S. Y., Jiang, F., & He, Y. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.17 · Cited by 28
Li, X., Jiang, L., Yang, M., Wu, Y., Sun, S., & Sun, J. (2014) · Journal of Diabetes Research · doi:10.1155/2014/398518 · Cited by 28
Effect of Sipjeondaebo-Tang on Cancer-Induced Anorexia and Cachexia in CT-26 Tumor-Bearing Mice
Choi, Y. K., Jung, K. Y., Woo, S., Yun, Y. J., Jun, C., Park, J. H., Shin, Y. C., Cho, S., & Ko, S. (2014) · Mediators of Inflammation · doi:10.1155/2014/736563 · Cited by 28
From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis?
Chen, C., & Tsai, C. (2013) · Rheumatology · doi:10.1093/rheumatology/ket255 · Cited by 29
Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases
Salvatore, T., Nevola, R., Pafundi, P. C., Monaco, L., Ricozzi, C., Imbriani, S., Rinaldi, L., & Sasso, F. C. (2019) · Nutrients · doi:10.3390/nu11081878 · Cited by 29
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 30
Metabolic Hormones Modulate Macrophage Inflammatory Responses
Batty, M. J., Chabrier, G., Sheridan, A., & Gage, M. (2021) · Cancers · doi:10.3390/cancers13184661 · Cited by 27
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 33
Mansur, R. B., Fries, G. R., Trevizol, A. P., Subramaniapillai, M., Lovshin, J. A., Lin, K., Vinberg, M., Ho, R., Brietzke, E. M., & McIntyre, R. S. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.10.007 · Cited by 26
Wang, L., Zhang, L., Ma, R., Zhang, Y., Chang, Q., & Yin, D. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf053 · Cited by 26
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Chen, T., Hu, E.-H., Chen, D., Lin, Y., Chou, T., Lin, M., Yang, N., Wang, C., Hung, M., & Tsai, M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30952 · Cited by 28
Packer, M., Lam, C. S. P., Butler, J., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.052 · Cited by 28
Ghebrehiwet-Kuflom, J., Mehta, A., Lim, P., Dahle, S. E., & Isseroff, R. R. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.08.045 · Cited by 30
GLP-1 signaling is required for improvement of glucose tolerance by osteocalcin
Mizokami, A., Mukai, S., Gao, J., Kawakubo‐Yasukochi, T., Otani, T., Takeuchi, H., Jimi, E., & Hirata, M. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0288 · Cited by 27
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 27
Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling
Pastel, E., Joshi, S., Knight, B., Liversedge, N., Ward, R., & Kos, K. (2016) · Nutrition and Diabetes · doi:10.1038/nutd.2016.44 · Cited by 25
Gong, Q., Rajagopalan, S., & Zhong, J. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.06.076 · Cited by 28
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice
Marques, A. P., Cunha‐Santos, J., Leal, H., Sousa-Ferreira, L., de Almeida, L. P., Cavadas, C., & Rosmaninho‐Salgado, J. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.11.012 · Cited by 25
Kumar, S., Basu, M., Ghosh, P., Pal, U., & Ghosh, M. K. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.12.019 · Cited by 25
Li, X., Jiang, L., Yang, M., Wu, Y., Sun, S., & Sun, J. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0156-8 · Cited by 24
DPP-4 Inhibitors as a Savior for COVID-19 Patients with Diabetes
Nag, S., Mandal, S., Mukherjee, O., Mukherjee, S., & Kundu, R. (2023) · Future Virology · doi:10.2217/fvl-2022-0112 · Cited by 22
Hu, C., Zhang, G., Sun, D., Han, H., & Hu, S. (2013) · Obesity Surgery · doi:10.1007/s11695-013-0976-1 · Cited by 23
Shah, H., Morieri, M. L., Marcovina, S. M., Sigal, R. J., Gerstein, H. C., Wagner, M. J., Motsinger‐Reif, A. A., Buse, J. B., Kraft, P. L., Mychaleckyj, J. C., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1638 · Cited by 23
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Wang, Y. Y., Wang, Y., Qi, X.-Y., Liao, Z., Mai, Y.-N., & Xiao, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839849 · Cited by 24
Avogaro, A., de Kreutzenberg, S. V., Morieri, M. L., Fadini, G. P., & Prato, S. D. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00247-9 · Cited by 22
Anti-inflammatory effects of GLP-1 in patients with COVID-19
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1964955 · Cited by 21
GLP-1-mediated gene therapy approaches for diabetes treatment
Tasyurek, H. M., Altunbaş, H., Canatan, H., Griffith, T. S., & Şanlıoğlu, S. (2014) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2014.7 · Cited by 22
Jensen, S. B. K., Lundgren, J. R., Janus, C., Juhl, C. R., Olsen, L. M., Rosenkilde, M., Holst, J. J., Stallknecht, B. M., Madsbad, S., & Torekov, S. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031431 · Cited by 20
Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice
Liu, D., Gu, J., Shao, W., Pang, J., Qian, X., & Jin, T. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.08.012 · Cited by 21
Obesity-related glomerulopathy: recent advances in inflammatory mechanisms and related treatments
Guan, Y., Wei, X., Li, J., Zhu, Y., Luo, P., & Luo, M. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae035 · Cited by 20
Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease
Zhang, C., Shi, Y., Liu, C., Sudesh, S. M., Zhao, H., Li, P., Liu, Q., Ma, Y., Shi, A., & Cai, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02273-4 · Cited by 24
Yang, Q., & Wang, F. (2016) · Gynecologic and Obstetric Investigation · doi:10.1159/000446951 · Cited by 20
Gut–adipose tissue crosstalk: A bridge to novel therapeutic targets in metabolic syndrome?
Silva, D., & Matafome, P. N. (2020) · Obesity Reviews · doi:10.1111/obr.13130 · Cited by 22
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“Similar antiinflammatory effects of GLP-1 have been reported in human macrophage cell lines (66), and systemic effects of GLP-1 agonists on macrophage infiltration have been previously reported (67).”
Li, Y., Fan, Q., Pang, R., Cai, L., Qi, J., Chen, W., Zhang, Y., Chen, C., Yu, W., & Li, P. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03465-9 · Cited by 22
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment
Neha, N., Wali, Z., Pinky, P., Hattiwale, S. H., Jamal, A., & Parvez, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102134 · Cited by 19
ALVARES, D. C. L., HOFFMAN, S. S., Stankovic, B., & Adeli, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.12.010 · Cited by 21
Chung, Y. W., Lee, J., Lee, J. Y., Ju, H. H., Lee, Y., Jee, D. H., Ko, S., & Choi, J. A. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.01.011 · Cited by 18
Self-citationErdoğan, M. A., Taşkıran, E., Yiğittürk, G., Erbaş, O., & Taşkıran, D. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22415 · Cited by 18
González-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 20
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., Deng, X., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1066 · Cited by 20
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Rizvi, A. A., Janež, A., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01170-3 · Cited by 18
Wang, S., Zhang, B., Chang, X., Zhao, H., Zhang, H., Zhao, T., & Qi, H. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2191135 · Cited by 19
Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue
Xian, Y., Chen, Z., Deng, H., Cai, M., Liang, H., Xu, W., Weng, J., & Xu, F. L. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0639 · Cited by 17
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Capturing the multifaceted function of adipose tissue macrophages
Matz, A. J., Qu, L., Karlinsey, K., Vella, A. T., & Zhou, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148188 · Cited by 16
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Identification and characterization of adipose surface epitopes
Onogi, Y., Khalil, A., & Ussar, S. (2020) · Biochemical Journal · doi:10.1042/bcj20190462 · Cited by 16
Bakkar, N. Z., AlZaim, I., & EL‐Yazbi, A. F. (2022) · Clinical Science · doi:10.1042/cs20220404 · Cited by 19
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 14
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Panfili, E., Frontino, G., & Pallotta, M. T. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1171091 · Cited by 14
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 14
Riedinger, C. J., Sakach, J. C., Maples, J. M., Fulton, J., Chippior, J., OʼDonnell, B., O’Malley, D. M., & Chambers, L. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.008 · Cited by 17
Wegeberg, A., Meldgaard, T., Bæk, A., Drewes, A. M., Vyberg, M., Jessen, N., Brock, B., & Brock, C. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13575 · Cited by 16
Ekhzaimy, A. A., Masood, A., Benabdelkamel, H., Elhassan, T., Musambil, M., & Alfadda, A. A. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221094322 · Cited by 15
Izaguirre, M., Gómez‐Ambrosi, J., Rodríguez, A., Ramírez, B., Becerril, S., Valentí, V., Moncada, R., Unamuno, X., Silva, C., de la Higuera, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040479 · Cited by 14
Hoteit, B. H., Kotaich, J., Ftouni, H., Hazime, F., Safawi, A., Masri, R., & Marwani, M. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251383064 · Cited by 18
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 13
Chemerin as a Driver of Cardiovascular Diseases: New Perspectives and Future Directions
Imiela, A. M., Stępnicki, J., Zawadzka, P. S., Bursa, A., & Pruszczyk, P. (2025) · Biomedicines · doi:10.3390/biomedicines13061481 · Cited by 16
He, S., Wu, W., Wan, Y., Nandakumar, K. S., Cai, X., Tang, X., Liu, S., & Yao, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01230 · Cited by 12
Role of Incretin Hormones in Bowel Diseases
Zietek, T., Waldschmitt, N., & Rath, E. (2017) · Endocrine development · doi:10.1159/000475731 · Cited by 13
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 13
Obesity drugs have another superpower: taming inflammation
Lenharo, M. (2024) · Nature · doi:10.1038/d41586-024-00118-4 · Cited by 12
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 14
Mahgoub, S., Fatahala, S. S., Sayed, A. I., Atya, H. B., Shehry, M. F. E., Afifi, H., Awad, S. M., El-Hameed, R. H. A., & Taha, H. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106092 · Cited by 11
The role of TNF in metabolic disorders and liver diseases
Xu, C., Ezzi, S. H. A., Zou, X., Dong, Y., Alhaskawi, A., Zhou, H., Kota, V. G., Abdulla, M. H. A. H., Abdalbary, S. A., & Lu, H. J. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156933 · Cited by 11
Treatment with sitagliptin exacerbates the M2 phenotype in macrophages in vitro
Quadros-Pereira, L., Nery-Neto, J. A. D. O., da Silva, E. M., Doretto-Silva, L., Yariwake, V. Y., Câmara, N. O. S., & Andrade‐Oliveira, V. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113730 · Cited by 10
Quitete, F. T., Nobre, J. L., Peixoto‐Silva, N., de Moura, E. G., Lisboa, P. C., & OLIVEIRA, E. B. D. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400666 · Cited by 10
Song, Y., Lu, Z., Zhang, X., Xu, J., Gong, M., Meng, L., Gong, Z., & Zheng, B. (2022) · Aquaculture Research · doi:10.1111/are.16123 · Cited by 10
DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient
Cosenso‐Martin, L. N., Giollo-Júnior, L. T., & Vilela-Martin, J. F. (2015) · Medicine · doi:10.1097/md.0000000000001068 · Cited by 10
Metadata
- Authors
- Lee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S.
- Affiliations
- Gachon University (KR)
- Gachon University Gil Medical Center (KR)
- Ajou University (KR)
- Seoul National University (KR)
- Corresponding author
- Jun, H.-S.
- Venue
- Diabetologia
- Published
- 2012-06-22
- Volume
- 55
- Issue
- 9
- Pages
- 2456-2468
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1993624198
- Cited by
- 319
- References
- 47
- Citations by year
- 2026: 31 · 2025: 34 · 2024: 35 · 2023: 29 · 2022: 25 · 2021: 24 · 2020: 17 · 2019: 26 · 2018: 17 · 2017: 15 · 2016: 17 · 2015: 17 · 2014: 18 · 2013: 12 · 2012: 2
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- AJOU Open Repository (Ajou University) (submittedVersion)
- Funders
- National Research Foundation
- National Research Foundation of Korea (A062260)
- Korea Science and Engineering Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, adipose tissue macrophages, adipose tissue inflammation, obesity, type 2 diabetes, insulin resistance, ob/ob mice, adipocyte size, lipogenic gene expression, macrophage polarization, NF-κB, JNK, exendin-4, lipopolysaccharide-induced inflammation, adipocyte inflammation, adipose tissue mass
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adipose Tissue, Animals, Anti-Inflammatory Agents, Gene Expression Regulation, Inflammation, Insulin Resistance, Macrophages, Mice, Obese, Obesity, NF-kappa B, Receptors, Glucagon, Body Fat Distribution, Mice, Glucagon-Like Peptide 1, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
